Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 24 04:00PM ET
Dollar change
Percentage change
IndexS&P 500 P/E44.69 EPS (ttm)4.65 Insider Own0.39% Shs Outstand83.90M Perf Week3.99%
Market Cap17.49B Forward P/E12.93 EPS next Y16.08 Insider Trans-14.56% Shs Float83.77M Perf Month-2.72%
Income418.00M PEG5.35 EPS next Q3.48 Inst Own98.43% Short Float2.70% Perf Quarter-6.90%
Sales12.90B P/S1.36 EPS this Y9.43% Inst Trans-2.81% Short Ratio3.01 Perf Half Y5.06%
Book/sh93.86 P/B2.22 EPS next Y8.34% ROA2.08% Short Interest2.26M Perf Year4.10%
Cash/sh6.38 P/C32.58 EPS next 5Y8.36% ROE4.27% 52W Range179.58 - 234.09 Perf YTD-8.51%
Dividend Est.2.23 (1.07%) P/FCF20.01 EPS past 5Y-11.14% ROI3.30% 52W High-11.17% Beta1.02
Dividend TTM2.78 (1.34%) Quick Ratio1.02 Sales past 5Y2.87% Gross Margin25.22% 52W Low15.79% ATR (14)3.53
Dividend Ex-DateMay 28, 2024 Current Ratio1.17 EPS Y/Y TTM-66.36% Oper. Margin8.80% RSI (14)48.78 Volatility1.72% 1.57%
Employees67000 Debt/Eq0.76 Sales Y/Y TTM-13.28% Profit Margin3.24% Recom1.85 Target Price245.69
Option/ShortYes / Yes LT Debt/Eq0.61 EPS Q/Q-330.17% Payout60.36% Rel Volume1.06 Prev Close207.97
Sales Surprise0.51% EPS Surprise1.32% Sales Q/Q-17.44% EarningsApr 25 BMO Avg Volume751.06K Price207.94
SMA20-0.23% SMA50-2.49% SMA200-2.47% Trades Volume793,528 Change-0.01%
Date Action Analyst Rating Change Price Target Change
Mar-25-24Upgrade Argus Hold → Buy $250
Feb-26-24Initiated Leerink Partners Outperform $260
Feb-09-24Initiated Evercore ISI In-line $240
Jan-03-24Initiated Barclays Equal Weight $222
Sep-06-23Initiated HSBC Securities Hold $210
Dec-12-22Downgrade Citigroup Buy → Neutral $275 → $250
Sep-19-22Downgrade Argus Buy → Hold
Aug-22-22Resumed Morgan Stanley Overweight $300
Jan-28-22Downgrade Deutsche Bank Buy → Hold $330 → $294
Jan-11-21Upgrade Argus Hold → Buy $245
Apr-24-24 10:25PM
Apr-22-24 09:16AM
05:34AM Loading…
Apr-19-24 05:34AM
Apr-18-24 12:10PM
Apr-16-24 08:42AM
Apr-15-24 07:00AM
Apr-12-24 09:10AM
Apr-11-24 06:59AM
Apr-10-24 06:49AM
Apr-09-24 09:03AM
Apr-08-24 09:34AM
07:09AM Loading…
Apr-05-24 07:00AM
Apr-03-24 11:01AM
Apr-02-24 11:20AM
Apr-01-24 12:42PM
Mar-30-24 01:30AM
Mar-29-24 09:00AM
Mar-28-24 11:08PM
Mar-27-24 07:00AM
07:03AM Loading…
Mar-25-24 07:03AM
Mar-20-24 07:00AM
Mar-18-24 09:44AM
Mar-16-24 10:29AM
Mar-15-24 09:25AM
Mar-11-24 11:00AM
Mar-08-24 10:26AM
Mar-07-24 07:00AM
Mar-05-24 07:00AM
Feb-27-24 12:08AM
Feb-26-24 08:45AM
Feb-21-24 12:00PM
Feb-19-24 06:28AM
Feb-16-24 09:41AM
Feb-15-24 03:29PM
Feb-12-24 09:16AM
Feb-08-24 10:00AM
Feb-07-24 09:05AM
Feb-05-24 08:16AM
Feb-01-24 04:55PM
Jan-31-24 07:00AM
Jan-16-24 06:58AM
Jan-12-24 06:57AM
Jan-11-24 11:21AM
Jan-10-24 08:02AM
Jan-05-24 04:45AM
Jan-02-24 07:00AM
Dec-29-23 09:23AM
Dec-26-23 03:59PM
Dec-21-23 09:03AM
Dec-17-23 05:05AM
Nov-30-23 07:46PM
Nov-27-23 08:35AM
Nov-24-23 07:21AM
Nov-22-23 05:04AM
Nov-20-23 07:00AM
Nov-16-23 07:00AM
Nov-08-23 07:00AM
Nov-06-23 05:07AM
Oct-31-23 01:17AM
Oct-28-23 02:29PM
Oct-27-23 08:30AM
Oct-26-23 11:13PM
Oct-23-23 06:26AM
Oct-19-23 10:01AM
Oct-16-23 08:30PM
Oct-13-23 08:28AM
Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schroeder Mark SEVP, Pres Diagnostics & COOApr 01 '24Sale217.296,4771,407,3875,036Apr 03 08:35 AM
Summy Amy B.EVP, Chief Marketing OfficerApr 01 '24Sale217.293,500760,5153,975Apr 03 08:34 AM
van der Vaart Sandra DEVP, Chief Legal OfficerMar 28 '24Sale216.743,553770,0777,637Mar 29 05:54 PM
Schroeder Mark SEVP, Pres Diagnostics & COOMar 07 '24Option Exercise117.092,119248,11410,084Mar 11 08:59 AM
Schroeder Mark SEVP, Pres Diagnostics & COOMar 07 '24Sale218.455,0481,102,7365,036Mar 11 08:59 AM
Summy Amy B.EVP, Chief Marketing OfficerMar 07 '24Sale218.4522749,5883,859Mar 11 08:56 AM
EISENBERG GLENN AChief Financial Officer, EVPFeb 21 '24Option Exercise163.6314,0542,299,65658,099Feb 22 03:05 PM
EISENBERG GLENN AChief Financial Officer, EVPFeb 21 '24Sale215.9734,5047,451,86623,595Feb 22 03:05 PM
DiVincenzo Jonathan P.EVP, Pres, Central Labs & IntlFeb 21 '24Sale215.49500107,7453,401Feb 22 03:04 PM
van der Vaart Sandra DEVP, Chief Legal OfficerFeb 13 '24Sale226.4523753,6697,637Feb 15 08:32 AM
van der Vaart Sandra DEVP, Chief Legal OfficerFeb 08 '24Sale222.0625957,5147,637Feb 09 12:19 PM
van der Vaart Sandra DEVP, Chief Legal OfficerFeb 05 '24Sale220.5719342,5707,637Feb 06 03:47 PM
Wilkinson Peter JSVP, Chief Accounting OfficerNov 16 '23Sale210.711,384291,6272,087Nov 20 12:23 PM
ANDERSON KERRII BDirectorAug 08 '23Sale211.575,0001,057,83215,275Aug 10 08:55 AM
van der Vaart Sandra DEVP, Chief Legal OfficerJun 29 '23Sale240.0021250,8807,605Jul 03 11:52 AM
Kirchgraber Paul RCEO, Covance Drug DevelopmentMay 19 '23Option Exercise182.514,300784,79317,246May 23 08:06 AM
Kirchgraber Paul RCEO, Covance Drug DevelopmentMay 19 '23Sale216.914,300932,70712,946May 23 08:06 AM
Schroeder Mark SEVP, Pres Diagnostics & COOMay 18 '23Option Exercise130.601,500195,9008,187May 22 03:08 PM
Schroeder Mark SEVP, Pres Diagnostics & COOMay 18 '23Sale216.771,500325,1556,687May 22 03:08 PM